Vernal keratoconjunctivitis: A severe allergic eye disease with remodeling changes

Pediatric Allergy and Immunology

Volumn 25, Issue 4, 2014, Pages 314-322

  Vichyanond, Pakit ^a   Pacharn, Punchama ^a   Pleyer, Uwe ^b   Leonardi, Andrea ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Allergic conjunctivitis; Cobblestone; Cornea ulcer; Horner trantas dot; Vernal keratoconjunctivitis

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; EPINASTINE; LEVOCABASTINE; LODOXAMIDE; OLOPATADINE; TACROLIMUS; CYCLOSPORIN; DIBENZOXEPIN DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LODOXAMIDE ETHYL; NONSTEROID ANTIINFLAMMATORY AGENT; OXAMIC ACID;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; BLINDNESS; CATARACT; CORNEA ULCER; DISEASE SEVERITY; EPIPHORA; EYE DISCHARGE; EYE INFECTION; EYE IRRITATION; EYE SURGERY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; OCULAR PRURITUS; PATHOGENESIS; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VERNAL CONJUNCTIVITIS; VISUAL IMPAIRMENT; ANALOGS AND DERIVATIVES; CHILD; COMPLICATION; CONJUNCTIVITIS, ALLERGIC; CORNEAL ULCER; EOSINOPHIL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PATHOLOGY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLINDNESS; CHILD; CONJUNCTIVITIS, ALLERGIC; CORNEAL ULCER; CYCLOSPORINE; DIBENZOXEPINS; EOSINOPHILS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; IMMUNOSUPPRESSION; OXAMIC ACID;

EID: 84904727539     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12197     Document Type: Review

References (86)

1. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002: 21: 319-39.
2. Leonardi A, Busca F, Motterle L, et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand 2006: 84: 406-10.
3. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol 2013: 97: 9-14.
4. Bonini S, Lambiase A, Marchi S, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000: 107: 1157-63.
5. Kansakar I. Profile of vernal keratoconjunctivitis in Nepal: a hospital based study. Nepal Med Coll J 2011: 13: 92-5.
6. Bonini S, Lambiase A, Schiavone M, et al. Estrogen and progesterone receptors in vernal keratoconjunctivitis. Ophthalmology 1995: 102: 1374-9.
7. Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol 2003: 21: 25-30.
8. Bremond-Gignac D, Donadieu J, Leonardi A, et al. Prevalence of vernal keratoconjunctivitis: a rare disease? Br J Ophthalmol 2008: 92: 1097-102.
9. McMoli TE, Assonganyi T. Limbal vernal kerato-conjunctivitis in Yaounde, Cameroon. A clinico-immunology study. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 1991: 68: 157-70.
10. De Smedt SK, Nkurikiye J, Fonteyne YS, et al. Vernal keratoconjunctivitis in school children in Rwanda: clinical presentation, impact on school attendance, and access to medical care. Ophthalmology 2012: 119: 1766-72.
11. Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991: 98: 1679-84.
12. Baryishak YR, Zavaro A, Monselise M, et al. Vernal keratoconjunctivitis in an Israeli group of patients and its treatment with sodium cromoglycate. Br J Ophthalmol 1982: 66: 118-22.
13. Neumann E, Gutmann MJ, Blumenkrantz N, Michaelson IC. A review of four hundred cases of vernal conjunctivitis. Am J Ophthalmol 1959: 47: 166-72.
14. Das D, Khan M, Gul A, Alam R. Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. J Pak Med Assoc 2011: 61: 239-41.
15. Reddy JC, Basu S, Saboo US, et al. Management, clinical outcomes, and complications of shield ulcers in vernal keratoconjunctivitis. Am J Ophthalmol 2013: 155: e1.
16. Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009: 25: 365-72.
17. Smedt SD, Nkurikiye J, Fonteyne Y, et al. Vernal keratoconjunctivitis in school children in Rwanda and its association with socio-economic status: a population-based survey. Am J Trop Med Hyg 2011: 85: 711-7.
18. Leonardi A, Bogacka E, Fauquert JL, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy 2012: 67: 1327-37.
19. Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol 2007: 7: 436-41.
20. Griffin RY, Sarici A, Unal M. Acquired ptosis secondary to vernal conjunctivitis in young adults. Ophthal Plast Reconstr Surg 2006: 22: 438-40.
21. Keklikci U, Soker SI, Soker Cakmak S, et al. Unilateral vernal keratoconjunctivitis: a case report. Eur J Ophthalmol 2007: 17: 973-5.
22. Leonardi A, Lazzarini D, Bortolotti M, et al. Corneal confocal microscopy in patients with vernal keratoconjunctivitis. Ophthalmology 2012: 119: 509-15.
23. Demirbas NH, Pflugfelder SC. Topographic pattern and apex location of keratoconus on elevation topography maps. Cornea 1998: 17: 476-84.
24. Totan Y, Hepsen IF, Cekic O, et al. Incidence of keratoconus in subjects with vernal keratoconjunctivitis: a videokeratographic study. Ophthalmology 2001: 108: 824-7.
25. Kaya V, Karakaya M, Utine CA, et al. Evaluation of the corneal topographic characteristics of keratoconus with orbscan II in patients with and without atopy. Cornea 2007: 26: 945-8.
26. Smith VA, Matthews FJ, Majid MA, Cook SD. Keratoconus: matrix metalloproteinase-2 activation and TIMP modulation. Biochim Biophys Acta 2006: 1762: 431-9.
27. Leonardi A, Sathe S, Bortolotti M, et al. Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy 2009: 64: 710-7.
28. Leonardi A, Brun P, Abatangelo G, et al. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci 2003a: 44: 3052-8.
29. Messmer EM, May CA, Stefani FH, et al. Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. Am J Ophthalmol 2002: 134: 816-21.
30. Trocme SD, Kephart GM, Allansmith MR, et al. Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol 1989: 108: 57-63.
31. Leonardi A, Jose PJ, Zhan H, Calder VL. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003b: 110: 487-92.
32. Kumagai N, Fukuda K, Fujitsu Y, et al. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog Retin Eye Res 2006: 25: 165-87.
33. Leonardi A, Radice M, Fregona IA, et al. Histamine effects on conjunctival fibroblasts from patients with vernal conjunctivitis. Exp Eye Res 1999: 68: 739-46.
34. Abu El-Asrar AM, Al-Mansouri S, Tabbara KF, et al. Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond) 2006: 20: 71-9.
35. Dogru M, Matsumoto Y, Okada N, et al. Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis. Allergy 2008: 63: 1324-34.
36. Dogru M, Okada N, Asano-Kato N, et al. Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis. Clin Exp Allergy 2006: 36: 1556-65.
37. Thornton CA, Macfarlane TV, Holt PG. The hygiene hypothesis revisited: role of materno-fetal interactions. Curr Allergy Asthma Rep 2010: 10: 444-52.
38. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999: 354: 541-5.
39. Koulikovska M, van der Ploeg I, Herrmann B, Montan PG. Respiratory syncytial virus and chlamydia are not detectable by PCR in ongoing vernal keratoconjunctivitis. Ocul Immunol Inflamm 2001: 9: 253-7.
40. Heaton T, Mallon D, Venaille T, Holt P. Staphylococcal enterotoxin induced IL-5 stimulation as a cofactor in the pathogenesis of atopic disease: the hygiene hypothesis in reverse? Allergy 2003: 58: 252-6.
41. Caliskan M, Bochkov YA, Kreiner-Moller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med 2013: 368: 1398-407.
42. Verin P, Allewaert R, Joyaux JC, et al. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. Eur J Ophthalmol 2001: 11: 120-5.
43. Fukuishi N, Kan T, Hirose K, et al. Inhibitory effect of epinastine on superoxide generation by rat neutrophils. Jpn J Pharmacol 1995: 68: 449-52.
44. Kohyama T, Takizawa H, Akiyama N, et al. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun 1997: 230: 125-8.
45. Kanai K, Asano K, Watanabe S, et al. Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Int Arch Allergy Immunol 2006: 140: 43-52.
46. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001: 87: 424-9.
47. Easty DL, Rice NS, Jones BR. Clinical trial of topical disodium cromoglycate in vernal kerato-conjunctivitis. Clin Allergy 1972: 2: 99-107.
48. Tabbara KF, Arafat NT. Cromolyn effects on vernal keratoconjunctivitis in children. Arch Ophthalmol 1977: 95: 2184-6.
49. Foster CS, Duncan J. Randomized clinical trial of topically administered cromolyn sodium for vernal keratoconjunctivitis. Am J Ophthalmol 1980: 90: 175-81.
50. el Hennawi M. A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis. Br J Ophthalmol 1994: 78: 365-9.
51. Leonardi A, Borghesan F, Avarello A, et al. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis. Br J Ophthalmol 1997: 81: 23-6.
52. Bonini S, Schiavone M, Magrini L, et al. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997: 104: 849-53.
53. Ciprandi G, Buscaglia S, Catrullo A, et al. Antiallergic activity of topical lodoxamide on in vivo and in vitro models. Allergy 1996: 51: 946-51.
54. Fahy GT, Easty DL, Collum LM, et al. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study. Eur J Ophthalmol 1992: 2: 144-9.
55. Caldwell DR, Verin P, Hartwich-Young R, et al. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis. Am J Ophthalmol 1992: 113: 632-7.
56. Leonardi AA, Smith LM, Fregona IA, et al. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide. Eur J Ophthalmol 1996: 6: 106-12.
57. Akman A, Irkec M, Orhan M. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis. Eye (Lond) 1998: 12(Pt 2): 291-5.
58. Leonardi A, Bremond-Gignac D, Bortolotti M, et al. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol 2007: 91: 1662-6.
59. Akpek EK, Hasiripi H, Christen WG, Kalayci D. A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis. Ophthalmology 2000: 107: 263-9.
60. Centofanti M, Schiavone M, Lambiase A, et al. Efficacy of mipragoside ophthalmic gel in vernal keratoconjunctivitis. Eye (Lond) 1996: 10(Pt 4): 422-4.
61. Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997: 45: 177-80.
62. Lambiase A, Leonardi A, Sacchetti M, et al. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol 2011: 128: 896-7 e9.
63. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et al. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004: 113: 355-8.
64. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 2006: 20: 407-16.
65. Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2010: 10: 469-77.
66. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000: 11: 478-83.
67. Oner V, Turkcu FM, Tas M, et al. Topical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safety. Jpn J Ophthalmol 2012: 56: 312-8.
68. Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis. Curr Allergy Asthma Rep 2013: 13: 308-14.
69. BenEzra D, Pe'er J, Brodsky M, Cohen E. Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 1986: 101: 278-82.
70. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990: 110: 641-5.
71. Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002: 89: 298-303.
72. Kilic A, Gurler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol 2006: 41: 693-8.
73. Spadavecchia L, Fanelli P, Tesse R, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 2006: 17: 527-32.
74. Attas-Fox L, Barkana Y, Iskhakov V, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008: 33: 545-9.
75. Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012: 30: 177-84.
76. Tam PM, Young AL, Cheng LL, Lam PT. Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis-case series. Br J Ophthalmol 2010: 94: 1405-6.
77. Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010: 26: 165-74.
78. Pucci N, Caputo R, Mori F, et al. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Int J Immunopathol Pharmacol 2010: 23: 865-71.
79. Pacharn P, Visitsunthorn N, Jirapongsananuruk O, Vichyanond P. Vernal keratoconjunctivitis (VKC) treated with 0.1% FK-506 ophthalmic ointment result of three years follow-up. J Allergy Clin Immunol 2007: 119: S153.
80. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011: 127: S1-55.
81. Lupez-Piedrahita E, Sánchez-Caraballo JM, Ramirez-Girado RH, Cardona-Villa R. Effectiveness of allergen immunotherapy in patients with vernal keratoconjunctivitis. Rev Alerg Mex 2013: 60: 11-6.
82. Tanaka M, Takano Y, Dogru M, et al. A comparative evaluation of the efficacy of intraoperative mitomycin C use after the excision of cobblestone-like papillae in severe atopic and vernal keratoconjunctivitis. Cornea 2004: 23: 326-9.
83. Fujishima H, Fukagawa K, Satake Y, et al. Combined medical and surgical treatment of severe vernal keratoconjunctivitis. Jpn J Ophthalmol 2000: 44: 511-5.
84. Guo P, Kheirkhah A, Zhou WW, et al. Surgical resection and amniotic membrane transplantation for treatment of refractory giant papillae in vernal keratoconjunctivitis. Cornea 2013: 32: 816-20.
85. Sangwan VS, Jain V, Vemuganti GK, Murthy SI. Vernal keratoconjunctivitis with limbal stem cell deficiency. Cornea 2011: 30: 491-6.
86. Sangwan VS, Murthy SI, Vemuganti GK, et al. Cultivated corneal epithelial transplantation for severe ocular surface disease in vernal keratoconjunctivitis. Cornea 2005: 24: 426-30.